MorphoSys Appoints Dr Arndt Schottelius as Chief Development Officer and Member of the Management Board

17-Dec-2008 - Germany

MorphoSys AG appointed Dr Arndt Schottelius (42), as its first Chief Development Officer, responsible for coordinating the Group's expanding therapeutic antibody development activities including pre-clinical and clinical drug development. Dr Schottelius joins MorphoSys from Genentech Inc., South San Francisco, where he served as the Director of immunology, Tissue Growth & Repair Early Development and most recently as Medical Director, Immunology Development, directing late-stage clinical development studies for the anti-CD20 antibodies Rituximab and Ocrelizumab in rheumatoid arthritis. Prior to his position at Genentech, Dr Schottelius held science and management positions in immunology research at Berlex Biosciences, CA, USA, and Schering AG, Berlin, Germany. The appointment of Dr Schottelius will take effect on December 29, 2008.

During his career Dr Schottelius has established a successful track record of advancing therapeutics from late stage research into clinical development. He has gathered extensive experience in discovery and in-licensing activities, portfolio management, pre-clinical and clinical development as well as FDA negotiations and regulatory filings. After medical studies in Germany, the United Kingdom and Switzerland Dr Schottelius received his PhD and MD degrees from the Albert-Ludwigs-University, Freiburg, Germany. Subsequently he practiced medicine as a resident physician in gastroenterology at the Charité University Hospital, Berlin, Germany, and held a research fellowship from the Crohn's & Colitis Foundation of America at the University of North Carolina at Chapel Hill before moving into the pharmaceutical industry.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous